Metabolic Characterization of Space Occupying Lesions of the Brain
Metabolic Characterization of Space Occupying Lesions of the Brain Using in Vivo MR- (Spectroscopic) Imaging at 3 Tesla and 7 Tesla
Insel Gruppe AG, University Hospital Bern
55 participants
Sep 1, 2021
OBSERVATIONAL
Conditions
Summary
High field MR-technologies are expected to boost metabolic spectroscopic imaging (MRSI), but also CEST-MRI. This is due to the fact that increased SNR is available which can be used to increase the spatial resolution of all sequences, or reduction of measurement times. Recent findings has shown that MRSI can be used to evaluate the isocitrate dehydrogenase (IDH) status of gliomas, a brain tumor type which is most often diagnosed in humans. Patients with IDH-mutated gliomas have a much longer survival time that IDH-wildtype. In IDH-mutated gliomas the substance 2-hydroxy-glutarate (2HG) is found, whereas in IDH-wildtype gliomas it is not. The underlying trial aims to measure 2HG directly with different MRSI sequences at 3 Tesla (3T) and 7 Tesla (7T) magnetic field strength. Apart from MRSI-techniques for IDH-typing it has been shown that CEST-imaging can also be performed to determine the IDH-status of gliomas. A total of 75 patients and 50 healthy controls will be examined in this study to evaluate the most accurate method for pre-operative IDH-status determination.
Eligibility
Inclusion Criteria3
- Healthy people who are able to lie in the MR scanner for one hour;
- Patients with suspected mass in the brain
- Written informed consent
Exclusion Criteria7
- Persons under the age of 18
- Persons who are mentally unable to choose to participate
- Pregnant women
- Patients with oncological findings or neurodegenerative findings in the past
- Wearing active implants (e.g. pacemakers and neurostimulators)
- Emergency patients
- Persons with tattoos on the head or neck area
Interventions
The MR-scans performed at 3T and 7T are performed to evaluate whether high field MR-examinations bring an advantage to the patient in determining the IDH-status of the glioma. Two MRSI/CEST sequences will be tested against each other.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04233788